Antiretroviral Agents in HIV-1

Antiretroviral Agents in HIV

DHHS HIV GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/65244

Contents of this Issue

Navigation

Page 22 of 25

Elimination Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool Serum/ Half-life 3.8 hrs Storage Store at room temperature (up to 25ºC or 77ºF). Reconstituted solution should be stored under refrigeration at 2ºC-8ºC (36ºF-46ºF) and used within 24 hours. Adverse Events ▶ Local injection site reactions in almost 100% of patients (pain, erythema, induration, nodules and cysts, pruritus, ecchymosis) ▶ Increased bacterial pneumonia ▶ Hypersensitivity reaction (< 1%)— symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases; rechallenge is NOT recommended Serum/Half-life 14-18 hrs Elimination CYP3A4 substrate Adverse Events ▶ Abdominal pain ▶ Cough ▶ Dizziness ▶ Musculoskeletal symptoms ▶ Pyrexia ▶ Rash ▶ Upper respiratory tract infections ▶ Hepatotoxicity ▶ Orthostatic hypotension 21

Articles in this issue

Archives of this issue

view archives of Antiretroviral Agents in HIV-1 - Antiretroviral Agents in HIV